Navigation Links
Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
Date:5/20/2008

Systemic Hypertension

An acute elevation of blood pressure, or acute hypertension, is a life-threatening condition that can cause permanent damage to the brain, heart, kidneys and blood vessels. It occurs in nearly 50 percent of patients presenting to the hospital with acute heart failure and is a common occurrence for patients with renal dysfunction. It is critical to rapidly manage and maintain optimal blood pressure to minimize risk of death and damage to vital organs. Of the over 35 million people in the United States with hypertension, over one million people each year will have one or more acute episodes of high blood pressure, requiring treatment in an acute care setting.

About Congestive Heart Failure (CHF)

Currently in the U.S., CHF affects nearly 5 million people with 550,000 new cases of CHF diagnosed each year. Despite the treatment of CHF with multiple drugs, almost all CHF patients will experience at least one episode of acute CHF that requires treatment with intravenous medications in the hospital. There were over 1,100,000 hospitalizations for CHF in 2004. Congestive heart failure has tremendous human and financial costs. Estimated direct costs in the U.S. for CHF were $29.6 billion in 2006.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company primarily focused on discovering and developing targeted, receptor-specific peptide and small molecule therapeutics, including melanocortin ("MC")-based therapeutics. Therapeutics affecting the activity of the MC family of receptors may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, cachexia, hemorrhagic shock and inflammation-related diseases. The Company is exploring other receptor-specific therapeutics, including natriuretic peptide receptor A ("NPRA") agonist compounds for use in treatment of acute systemic hypertension, congestive heart failure and other d
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
2. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
3. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
4. CoreSpine Technologies Expands Spinal Disc Site Preparation Efforts
5. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
6. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
7. Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology
8. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
9. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
10. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
11. Senesco Technologies Initiates Preclinical Studies for Cancer Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  TNI BioTech, Inc. ... company focused on the development, marketing and distribution ... filed definitive proxy materials with the Securities and ... Meeting of Shareholders to be held on Thursday, ... Time. The record date for determining those shareholders ...
(Date:7/28/2014)... ANGELES , SINGAPORE, and TOKYO , ... announced that it has appointed Roger Crystal , ... most recently served in the Global Business Development Product ... "Roger,s experience in developing business strategy and ... valuable as we continue to partner with biotechnology and ...
(Date:7/28/2014)... 28, 2014 PDL BioPharma, Inc. (PDL) (NASDAQ: ... its second quarter 2014 financial results for the period ended ... close. PDL,s management will host a conference call and webcast ... financial results.  A slide presentation relating to the call will ... Conference Call Details To access the live ...
Breaking Medicine Technology:TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development 2PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2
... SYDNEY, Australia, June 16 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; ... Limited to,manage and provide eligible patients worldwide with ... The program will allow patients who are unable ... are considered by their physician,to be suffering from ...
... Claims Cover Anti-Viral Applications of Novel Targeted Agents Under ... Company,s Anti-Phospholipid Technology Platform -, - Anti-Viral ... Presented at American Association of Immunologists Annual Meeting ... (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing ...
Cached Medicine Technology:Pharmaxis Establishes Named Patient Program for Bronchitol 2Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio 2Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio 3Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio 4
(Date:7/28/2014)... A lush green lawn offers the perfect ... However, the summer heat, lack of rain, foot traffic, and ... and unhealthy. The Grounds Guys recommends these suggestions for nurturing ... once a week and set the height on the lawn ... grass roots from heat and allows roots to retain water ...
(Date:7/28/2014)... 28, 2014 An estimated 68,000 women ... metastatic breast and prostate cancers – an aggressive form ... spread to other parts of the body, such as ... Drexel University College of Medicine have developed ... inhibits metastatic progression by blocking tumor cells from β€œre-seeding.” ...
(Date:7/28/2014)... 28, 2014 Ticket Down is ... tickets in Dallas, TX at the Cotton Bowl. The ... the USA and it is an eight team tourney. ... world including teams from La Liga, Serie A, English Premier ... battle it out on the pitch include: Manchester United, ...
(Date:7/28/2014)... 2014 Ticket Down is a ... in Miami, FL at the Sun Life Stadium in early ... between Argentina and Brazil has is one that has continues ... rivalries are forming on a consistent basis. The rivalry ... height in the recent 2014 World Cup. To the ...
(Date:7/28/2014)... Steven Reinberg HealthDay ... People who have dementia and heart rhythm irregularities are more ... research has found. In fact, the study of more ... to 80 percent more likely to get a pacemaker than ... from this study is why folks with dementia are so ...
Breaking Medicine News(10 mins):Health News:Nurturing Lawns in the Summer Heat: The Grounds Guys® Offers Tips on Caring for Lawns This Summer 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 3Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 2Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 3Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3
... Deficit Hyperactivity Disorder (ADHD) is a prevailing issue in ... every year. A new study reveals that Pycnogenol, (pic-noj-en-all), ... French maritime pine tree, reduces ADHD in children. The ... and dopamine, resulting in a decrease of ADHD. ...
... NSERC Idea to Innovations grant and an Ontario Early ... and Nanosystems Laboratory ( http://amnl.mie.utoronto.ca ) at the University ... technology for automated microinjection of zebrafish embryos. , ... microrobotic system is capable of immobilizing a large number ...
... (Sept. 12, 2007) For the first time in ... ocean corals in its annual report of wildlife going ... by Conservation International (CI) and implemented jointly with the ... Charles Darwin Research Station and other regional institutions to ...
... helps teens make better food choices as adults, study finds ... dinner with their families on a regular basis are also ... a new study shows. , These teens also go on ... , Reporting in the Journal of the American Dietetic ...
... Medical,Technologies, Inc. today reported to its board of ... to include England, Canada, New,Zealand and Australia. ... began to come in as a result of ... the ReBuilder System(R). Through,word of mouth and the ...
... may be the last taboo,in our society, a subject that ... to fear -- to be avoided no matter what the ... "Triumph" is the result of daily writing over the ... about Darlyne,s,impending death and Philip,s loss. They have written this ...
Cached Medicine News:Health News:New study: Pine bark extract reduces ADHD symptoms in children 2Health News:Corals added to IUCN Red List of Threatened Species for first time 2Health News:Corals added to IUCN Red List of Threatened Species for first time 3Health News:ReBuilder Medical Technologies, Inc. Reports International Sales Expansion 2Health News:ReBuilder Medical Technologies, Inc. Reports International Sales Expansion 3Health News:ReBuilder Medical Technologies, Inc. Reports International Sales Expansion 4Health News:'Triumph' -- Traveling Towards Death: Preparing for a New Life 2
... , Combined Advanced Technologies, The ... technologically advanced combination of high pressure ... Proprietary coextrusion process yields a remarkably ... conventional high pressure balloon materials., Non-Compliant ...
Used retrograde to dilate the ureter and establish a conduit for a flexible ureteroscope. Supplied sterile in peel-open packages. Intended for one-time use....
... Diameter; 5.4 Fr Straight Channel; 33 or ... MRO-7 Integral Operating Ureteroscopes offer a small ... easy access to the ureter for diagnosis ... Fr) is ideal for large operating instruments, ...
... self-dilating, semi-rigid autoclavable operating ureteroscope featuring distortion-free ... for an enhanced, clear image. The universal ... diopters. The direction of view is 5 ... straight access operating channel is ideal for ...
Medicine Products: